For instance, in multiple myeloma, pan-BET inhibition with JQ1(targeting BRD2/BRD3/BRD4/BRDT) increases expression of the NKG2D ligand MICA on tumor cells, enhancing susceptibility to NK-mediated cytotoxicity through a BRD4-dependent mechanism that downregulates c-MYC and alters miR-125b and IRF4 levels (86). Here, BRD2 is linked to plasma cell myeloma.